Ornithine Accumulation and ZBTB7A-Mediated Astrocyte Dysfunction in Realgar-Induced CNS Toxicity

Study Background and Research Question

Realgar, an arsenic-containing mineral used in traditional Chinese medicine (TCM), has a long history of clinical application. Despite its therapeutic uses, persistent beliefs in the safety of TCM have led to misuse and cases of chronic arsenic poisoning, resulting in systemic toxicity—including neurotoxicity [DOI:10.1002/advs.202502591]. The central nervous system (CNS) is particularly vulnerable, as arsenic can cross the blood–brain barrier and accumulate in the frontal lobe. Astrocytes, key glial cells supporting neuronal metabolism, are among the earliest CNS targets. This study investigates the molecular mechanisms connecting realgar-induced hepatic metabolic disruption to astrocyte dysfunction in the brain, focusing on the role of ornithine, the urea cycle intermediate, and the transcription factor ZBTB7A.

Key Innovation from the Reference Study

The central innovation lies in delineating a mechanistic liver–brain axis involving hepatic ornithine transcarbamylase (OTC), ornithine accumulation, and ZBTB7A-mediated transcriptional repression of glycolytic genes in astrocytes. By integrating metabolomics, single-cell transcriptomics, and targeted genetic and pharmacologic interventions, the authors demonstrate that realgar-induced OTC inhibition in the liver elevates circulating and cerebral ornithine. Ornithine, in turn, binds to ZBTB7A, enhancing its repression of glycolytic enzymes (Aldoa, Ldha, Pgam1) in astrocytes, resulting in decreased lactate production and energy deficit in the frontal lobe [paper, DOI:10.1002/advs.202502591]. This axis provides a direct molecular link between hepatic metabolic disturbance and CNS toxicity.

Methods and Experimental Design Insights

The study employs a multifaceted approach:

• In Vivo Models: Conditional intervention mouse models were generated, including Zbtb7a knockdown in astrocytes, hepatic OTC overexpression, and chrysophanol co-treatment groups. Mice were exposed to realgar to induce hepatotoxicity and neurotoxicity.
• In Vitro Models: C8-D1A astrocyte cell lines were transfected with siRNAs targeting Zbtb7a and treated with both inorganic arsenic (iAs³⁺) and ornithine to dissect direct molecular effects.
• Omics and Molecular Analyses: Single-cell transcriptome sequencing and metabolomic profiling were performed to map gene expression and metabolite changes in brain and liver tissues. Molecular docking assessed ornithine binding to ZBTB7A.
• Functional Assays: Neurobehavioral testing (learning/memory, exploration, anxiety), histopathology, and biochemical assays (lactic acid quantification, enzyme activity) were integrated to correlate molecular findings with physiological and behavioral phenotypes.

Protocol Parameters

• assay | lactic acid quantification in frontal lobe | nmol/mg protein (exact values in paper Figure 3c) | assesses astrocyte glycolytic output under realgar and ornithine exposure | paper | DOI:10.1002/advs.202502591
• assay | OTC activity assay in liver | U/g tissue (decrease quantified post-realgar) | confirms hepatic urea cycle disruption | paper | DOI:10.1002/advs.202502591
• assay | Ornithine supplementation in astrocyte culture | 2 mM (as used for in vitro exposure) | tests direct modulation of ZBTB7A and glycolytic gene expression | paper | DOI:10.1002/advs.202502591
• assay | Behavioral test (Morris water maze, open field) | latency (s), distance (cm), zone entries | correlates molecular/biochemical changes with cognitive and anxiety phenotypes | paper | DOI:10.1002/advs.202502591
• workflow_recommendation | L-Ornithine solubilization | ≥17.3 mg/mL in water, ≥0.64 mg/mL in ethanol (with ultrasonication) | enables flexible preparation for cell culture or animal studies | product_spec | APExBIO

Core Findings and Why They Matter

The principal findings can be summarized as follows:

• Hepatic OTC Inhibition: Realgar exposure inhibits hepatic OTC, a key urea cycle enzyme responsible for converting ornithine to citrulline. This inhibition leads to ornithine accumulation in both blood and brain [paper, DOI:10.1002/advs.202502591].
• Ornithine–ZBTB7A Interaction: Molecular docking and cellular assays reveal specific binding of ornithine to ZBTB7A, a transcription factor in astrocytes. Elevated ornithine enhances ZBTB7A-mediated repression of glycolytic genes (Aldoa, Ldha, Pgam1), resulting in decreased lactate production—a crucial neuronal energy substrate [paper, DOI:10.1002/advs.202502591].
• Energy Deficit and Neurotoxicity: The impaired glycolytic capacity of astrocytes leads to energy deficits in the frontal lobe, promoting neuronal apoptosis, oxidative stress, and behavioral deficits (impaired learning, anxiety-like behavior).
• Therapeutic Modulation: Chrysophanol, a compound from rhubarb, mitigates both CNS and hepatic toxicity by preserving glycolytic activity in astrocytes and restoring urea cycle function.

Collectively, these results establish a mechanistic basis for the observed neurological sequelae of realgar intoxication, which mirrors symptoms seen in hyperornithinemia and related metabolic disorders.

Comparison with Existing Internal Articles

Several internal resources elaborate the experimental and translational importance of L-Ornithine in amino acid metabolism and urea cycle research. For example, “L-Ornithine (B8919): Urea Cycle Intermediate for Metabolic Research” highlights how L-Ornithine serves as a model substrate in studies of ammonia detoxification and metabolic enzyme assays, directly supporting the type of mechanistic dissection performed in the reference study [workflow_recommendation]. Another article, “L-Ornithine at the Nexus of Metabolic Research,” discusses the relevance of high-purity, non-proteinogenic amino acids for probing CNS-liver metabolic crosstalk—an approach mirrored in the realgar toxicity model. These resources reinforce the reference paper’s rationale for integrating L-Ornithine as a critical analytical and experimental tool, especially in the context of urea cycle and CNS toxicity mechanisms.

Limitations and Transferability

While the study presents a robust mechanistic framework linking liver urea cycle dysfunction to astrocyte-mediated CNS toxicity, several limitations remain:

• Species and Model Specificity: Most findings derive from murine models and immortalized astrocyte lines, which may not fully capture human metabolic or neurobiological diversity [paper, DOI:10.1002/advs.202502591].
• Exogenous Dosing: The concentrations of realgar and ornithine used in animal and cell studies may exceed typical human exposure, warranting careful dose extrapolation.
• Clinical Translation: While pathomechanisms are clarified, direct intervention strategies (e.g., ZBTB7A modulation) remain to be validated in clinical settings.

Nonetheless, the cross-organ mechanistic insights are transferable to broader research on metabolic encephalopathies, hyperornithinemia syndromes, and toxin-induced neurodegeneration.

Research Support Resources

To experimentally model or dissect the urea cycle intermediate dynamics, the use of high-purity L-Ornithine (chemically (S)-2,5-diaminopentanoic acid) is recommended. Researchers can prepare L-Ornithine (SKU B8919) at concentrations up to ≥17.3 mg/mL in water or ≥0.64 mg/mL in ethanol with ultrasonication, facilitating its application in both cell-based and animal model workflows [product_spec, APExBIO]. For additional workflow guidance and troubleshooting strategies, relevant articles such as “Atomic Insights into Urea Cycle and CNS Mechanisms” provide evidence-based recommendations for deploying L-Ornithine in metabolic and neurotoxicology research.